New drug combo may shield transplant patients from debilitating immune attack
NCT ID NCT03680092
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This study tested whether a combination of two drugs, cyclophosphamide and abatacept, could lower the chance of developing chronic graft-versus-host disease (GVHD) after a stem cell transplant. GVHD happens when donor cells attack the patient's body. The trial included 43 adults with high-risk blood cancers. The goal was to see if this new approach works better than standard care at preventing moderate to severe GVHD one year after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.